ON Helix 2014

ON Helix 2014

02-07-2014 - 02-07-2014 Churchill College, Cambridge, United Kingdom

The ON Helix event aims to inform delegates of how to turn early stage inventions and ideas into innovative health treatments. It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business.

The ON Helix event aims to inform delegates of how to turn early stage inventions and ideas into innovative health treatments. It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business. 

The four main elements of the conference will be: 

VIP Keynote Presentation and panel debate

The conference will be opened with a Keynote Address from Dr Mene Pangalos, Executive Vice President Innovative Medicines and Early Research at AstraZeneca. He will be followed by a VIP panel discussion chaired by Sir Mike Rawlins, Chairman of the EAHSN and President of the Royal Society of Medicine. 

The panel will comprise Hermann Hauser, Sir Gregory Winterand Sir TomBlundell who will offer their insights into the translational research pathway and take questions from the floor.


Discussion on target validation challenges

This session will focus on the current approaches to target identification for innovative medicines; what data package constitutes target validation in the eyes of a pharmaceutical company and which technologies are enabling researchers to secure the required data.

The different approaches will be discussed by representatives from some of the most innovative companies in the field including Merck Sharp & Dohme, GE Healtchare andNeusentis.  


Case studies

This stream will feature interactive case studies from companies who have successfully translated assets from their technology. They will share their stories of how they packaged the assets they developed, what the key decision making points were and how they used networks to help achieve success. 


Enabling translational research in the UK

This stream will feature a round table discussion between key enablers of translational research in the UK including the Wellcome Trust, SROne and SynconaPartners. The speakers will address how their initiatives are helping meet the challenges identified and described during the day.

Who should attend?

  • Biotech and healthcare companies senior executives
  • Academic technology transfer executives
  • Pharma business and research development directors
  • Life science investors
  • Technical and professional service providers

Company Spotlight

ImmunoGen

ImmunoGen

Ario Pharma

ario-pharma-small.jpg

Ario Pharma is a UK-based biopharmaceutical company that focuses on the development of drugs for the treatment of respiratory indications.

Back to top